AC
ACET.US Adicet Bio Inc
- Market cap
- USD 27.4M
- P/E
- -
- P/B
- 0.27x
- ROE
- -78.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ACET.US undervalued?
Graham numberThe Graham number of Adicet Bio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Adicet Bio Inc fundamental analysis
No fundamental analysis for Adicet Bio Inc yet.
Adicet Bio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-spec…
Full company profileAdicet Bio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Adicet Bio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 547M | 559M | 8.18M | 995K | 17.9M | 9.73M | 25.0M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 135M | 559M | 8.10M | 995K | 17.9M | 9.73M | 25.0M | -6.10M | -6.47M | -6.38M | - |
| Operating Income | -1.00K | -18.9M | -15.0M | -31.4M | -39.2M | -61.4M | -72.6M | -152M | -128M | -122M | -84.9M |
| EBITDA | -1.00K | -33.8M | -14.9M | -26.9M | -38.1M | -60.4M | -67.0M | -137M | -111M | -110M | -74.7M |
| Net Income | -1.00K | -33.8M | -9.30M | -28.1M | -36.7M | -62.0M | -69.8M | -143M | -117M | -117M | -80.6M |
| EPS | 0.00 | -20 | -4.99 | -24 | -80 | -32 | -27 | -53 | -21 | -17 | -7.50 |
| Balance Sheet | |||||||||||
| Total Assets | 541M | 55.2M | 110M | 81.6M | 154M | 339M | 331M | 207M | 220M | 192M | 129M |
| Total Liabilities | 236M | 5.50M | 5.74M | 142M | 44.0M | 35.8M | 38.4M | 37.1M | 33.6M | 33.1M | 26.2M |
| Shareholders' Equity | 304M | 49.7M | 104M | -60.4M | 110M | 303M | 292M | 170M | 187M | 159M | 103M |
| Cash & Short-term Investments | 67.7M | 53.3M | 108M | 62.4M | 94.6M | 278M | 258M | 160M | 176M | 159M | 101M |
| Total Debt | 119M | 354M | 3.11M | 114M | 21.6M | 20.9M | 21.0M | 20.9M | 17.2M | 14.7M | 12.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 8.34M | -11.6M | -18.2M | -27.9M | -41.6M | -51.1M | -44.8M | -93.7M | -92.4M | -95.2M | -79.0M |
| Capital Expenditure | 617K | 44.0K | 876K | 1.07M | 990K | 13.0M | 16.8M | 4.46M | 1.12M | 1.74M | 393K |
| Free Cash Flow | 7.73M | -11.6M | -19.1M | -29.0M | -42.5M | -64.1M | -61.5M | -98.2M | -93.5M | -97.0M | -79.4M |
| Ratios | |||||||||||
| ROE | 0.0% | -68.0% | -8.9% | - | -33.4% | -20.5% | -23.9% | -83.8% | -62.8% | -73.4% | -78.5% |
| ROA | 0.0% | -61.2% | -8.5% | -34.5% | -23.8% | -18.3% | -21.1% | -68.8% | -53.2% | -60.7% | -62.5% |
| Net Profit Margin | 0.0% | -6.0% | -113.7% | -2,827.9% | -204.9% | -637.2% | -279.3% | - | - | - | - |
| Debt to Equity | 0.39x | 7.12x | 0.03x | - | 0.20x | 0.07x | 0.07x | 0.12x | 0.09x | 0.09x | 0.12x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Adicet Bio Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 7.08M | 4.20 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:16 on Dec 30, 2025.
Who owns Adicet Bio Inc
- Insiders 6.44%
- Institutions 65.83%
- Public & others 27.73%
- Shares outstanding 9.36M
- Free float 7.18M
Top funds holding ACET.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Franklin Biotechnology Discv A(acc)USD | 499K | 5.33% | +24.31% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 267K | 2.86% | +9.90% | Sep 2026 |
| Franklin Biotechnology Discovery A | 225K | 2.41% | 0.00% | Sep 2026 |
| Bridgeway Ultra-Small Company | 86.0K | 0.92% | 0.00% | Jun 2026 |
| Fidelity Extended Market Index | 35.8K | 0.38% | -23.31% | Sep 2026 |
| iShares Micro-Cap ETF | 21.7K | 0.23% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 17.3K | 0.19% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 17.3K | 0.19% | +8.91% | Sep 2026 |
| Dimensional US Small Cap ETF | 16.1K | 0.17% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 12.4K | 0.13% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 6.60K | 0.07% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.07K | 0.02% | -60.35% | Sep 2026 |
| 1290 VT Micro Cap K | 1.60K | 0.02% | 0.00% | Sep 2026 |
| DFA US Vector Equity Class F | 1.43K | 0.02% | 0.00% | Aug 2026 |
| DFA U.S. Vector Equity I | 478.00 | 0.01% | 0.00% | Sep 2026 |
| Dimensional Global Core Equity USD Acc | 418.00 | 0.00% | -0.24% | Sep 2026 |
Top institutions holding ACET.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 933K | 9.96% | -21.14% | Jun 2026 |
| Orbimed Advisors LLC | 845K | 9.02% | -17.82% | Jun 2026 |
| Franklin Templeton Inc | 627K | 6.69% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 433K | 4.62% | +13.33% | Jun 2026 |
| Vanguard Capital Management, LLC | 343K | 3.67% | +1.99% | Jun 2026 |
| Adage Capital Partners Gp LLC | 274K | 2.93% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 266K | 2.84% | +14.34% | Jun 2026 |
| Stonepine Capital Management Llc | 246K | 2.62% | +10.62% | Jun 2026 |
| Alyeska Investment Group, L.P. | 204K | 2.18% | 0.00% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 196K | 2.09% | 0.00% | Jun 2026 |
| The Carlyle Group Inc | 184K | 1.97% | 0.00% | Jun 2026 |
| NEXTBio Capital Management LP | 158K | 1.69% | 0.00% | Jun 2026 |
| Acadian Asset Management LLC | 125K | 1.33% | +5.67% | Jun 2026 |
| Two Sigma Investments LLC | 96.8K | 1.03% | +124.65% | Jun 2026 |
| Geode Capital Management, LLC | 95.6K | 1.02% | -5.44% | Jun 2026 |
| Dafna Capital Management LLC | 93.8K | 1.00% | 0.00% | Jun 2026 |
| Bridgeway Capital Management, LLC | 86.0K | 0.92% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 79.5K | 0.85% | 0.00% | Jun 2026 |
| Trexquant Investment LP | 78.0K | 0.83% | +78.63% | Jun 2026 |
| Jane Street Group LLC | 70.6K | 0.75% | +90.27% | Jun 2026 |
Adicet Bio Inc company profile
- Company name
- Adicet Bio Inc
- Ticker
- ACET.US
- Exchange
- USA Stocks
- Listed since
- Jan 26, 2018
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 102
- Fiscal year end
- December
- Address
- 131 Dartmouth Street, Boston, MA, United States, 02116
- Phone
- 650 503 9095
- Website
- adicetbio.com
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Adicet Bio Inc management
5- Dr. Blake Aftab Ph.D.Senior VP & Chief Scientific Officer · born 1981
- Dr. Lloyd Klickstein M.D., Ph.D.Interim Chief Medical Officer & Director · born 1957
- Mr. Brian Nicholas Harvey M.B.A.Chief Financial Officer · born 1961
- Dr. Donald Healey Ph.D.Chief Technology Officer · born 1962
- Ms. Amy LockeChief Human Resource Officer